The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

Fast Track Designation is given to drugs that are intended to treat serious conditions and or fill an unmet medical need.

Those with ALS have an average survival of around two to five years from diagnosis, with most ALS patients dying from ...

The author has a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 months, representing significant upside from its ...

Qure divested for $25M, advanced AMT-130 with FDA approvals, and building infrastructure. A strong balance sheet backs ...

Glenmark Pharmaceuticals seeks licensing deal for ISB 2001 drug candidate, plans growth with semaglutide in India.

Boston-based biotech PepGen Inc. (NASDAQ:PEPG) announced today it will discontinue all Duchenne muscular dystrophy (DMD) ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced that the results from the open label Phase 2 PROSPECT Study of tirabrutinib is to be ...

GRIN Therapeutics & Angelini Pharma ink exclusive collaboration to develop and commercialize radiprodil outside North America: New York Wednesday, May 28, 2025, 15:00 Hrs [IST] GR ...

Zydus Lifesciences announced that the U.S. Food and Drug Administration (USFDA) has granted Fast Track Designation to Usnoflast (ZYIL1), a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company, has announced that the USFDA has granted ‘Fast Track ...